NeOnc Technologies Holdings, Inc. (NTHI)
NASDAQ:NTHI
Want to see NTHI full AI Analyst Report?
NTHI Stock Chart & Stats
$8.88
--
Market closed
$8.88
--
Day’s Range― - ―
52-Week Range$3.20 - $12.99
Previous CloseN/A
VolumeN/A
Average Volume (3M)103.40K
Market Cap
$137.09M
Enterprise Value$96.38M
Total Cash (Recent Filing)$138.60K
Total Debt (Recent Filing)$346.05K
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 25, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.94
Shares Outstanding26,013,136
10 Day Avg. Volume39,098
30 Day Avg. Volume103,402
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-9.07
Price to Sales (P/S)3973.02
P/FCF Ratio-7.62
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.01K
Enterprise Value/Ebitda-2.74
Forecast
1Y Price Target
$16.00Price Target Upside80.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
UAE IND Clearance For NEO212UAE IND clearance establishes the first international regulatory pathway for NEO212, enabling trials outside the U.S. This diversifies regulatory risk, can accelerate patient enrollment and data generation, and creates an alternate route toward registrational evidence, reducing single-jurisdiction dependency.
Exclusive Patent Estate To 2038A globally licensed patent estate through 2038 provides a durable IP moat for NeOnc’s chemo agents and delivery platforms, supporting long-term competitive differentiation, potential licensing revenues, and investment protection for multi-year clinical and commercialization efforts in CNS oncology.
Phase 1 Complete; Phase 2 Dose SetCompletion of Phase 1 with a selected 610 mg Phase 2 dose, plus full enrollment of a NEO100 Phase 2a and early efficacy signals, meaningfully de-risks NeOnc’s lead programs versus preclinical peers and increases the probability of progressing to pivotal studies and long-term value creation.
Bears Say
Zero TTM Revenue; Large Cash BurnZero trailing revenue combined with roughly -$21.7M TTM operating and free cash flow means NeOnc cannot self-fund operations. Persistent cash burn constrains strategic flexibility, forces prioritization of programs, and makes long-term continuity dependent on external capital availability.
Negative Stockholders' EquityPersistently negative shareholders’ equity (~-$13.2M TTM) reflects accumulated deficits and weak capitalization. This structural weakness limits borrowing capacity, raises solvency concerns under stress, and increases dependence on dilutive financing or restrictive creditor terms for sustaining operations.
Reliance On Equity Financings; Dilution RiskRepeated private placements, a Series A preferred issuance and a $75M ATM program indicate structural reliance on capital markets. While these mechanisms provide liquidity, they create ongoing dilution risk, investor-concentration constraints, and make program continuity contingent on favorable market access.
NeOnc Technologies Holdings, Inc. News
NTHI FAQ
What was NeOnc Technologies Holdings, Inc.’s price range in the past 12 months?
NeOnc Technologies Holdings, Inc. lowest stock price was $3.20 and its highest was $12.99 in the past 12 months.
What is NeOnc Technologies Holdings, Inc.’s market cap?
NeOnc Technologies Holdings, Inc.’s market cap is $137.09M.
When is NeOnc Technologies Holdings, Inc.’s upcoming earnings report date?
NeOnc Technologies Holdings, Inc.’s upcoming earnings report date is Aug 25, 2026 which is in 66 days.
How were NeOnc Technologies Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is NeOnc Technologies Holdings, Inc. overvalued?
According to Wall Street analysts NeOnc Technologies Holdings, Inc.’s price is currently Undervalued.
Does NeOnc Technologies Holdings, Inc. pay dividends?
NeOnc Technologies Holdings, Inc. does not currently pay dividends.
What is NeOnc Technologies Holdings, Inc.’s EPS estimate?
NeOnc Technologies Holdings, Inc.’s EPS estimate is -0.16.
How many shares outstanding does NeOnc Technologies Holdings, Inc. have?
NeOnc Technologies Holdings, Inc. has 26,013,136 shares outstanding.
What happened to NeOnc Technologies Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NeOnc Technologies Holdings, Inc.?
Currently, no hedge funds are holding shares in NTHI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NeOnc Technologies Holdings, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (80.18% Upside)
$16.00 (80.18% Upside)
Insider Transactions
Bought Shares
Worth $424.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
284.28%
Trailing 12-Months
Asset Growth
-60.55%
Trailing 12-Months
Company Description
NeOnc Technologies Holdings, Inc.
Neonc Technologies Holdings, Inc. specializes in pioneering molecular advancements aimed at improving the targeted administration of therapies for central nervous system disorders. The company's leading pipeline candidate, NEO100, is presently undergoing Phase 2a clinical trials for the treatment of glioblastoma. Additionally, NEO212, a unique molecular construct chemically linking the chemotherapeutic agent temozolomide with perillyl alcohol, has successfully concluded its preclinical evaluation. This enterprise, founded in 2023, operates from its base in Los Angeles, California.
NTHI Stock 12 Month Forecast
Average Price Target
$16.00
▲(80.18% Upside)
Technical Analysis
Ownership Overview
31.23% Insiders
1.24% Mutual Funds
5.90% Other Institutional Investors
60.38% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---